Roivant Sciences (ROIV) - Stock Price & Dividends
Exchange: USA Stocks • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: BMG762791017
Roivant Sciences Ltd., listed under NASDAQ as ROIV, is a company that specializes in the development and commercialization of medications for inflammation and immunology. They have a unique approach known as Vants, which is a method used to develop and market their products and technologies, specifically targeting biopharmaceutical businesses, discovery-stage companies, and health technology startups.
One of their notable products in development is VTAMA, a topical solution designed for treating psoriasis and atopic dermatitis. Additionally, Roivant Sciences is working on batoclimab and IMVT-1402, fully human monoclonal antibodies that target the neonatal Fc receptor to address various IgG-mediated autoimmune conditions. Their portfolio also includes RVT-3101, an anti-TL1A antibody for managing ulcerative colitis and Crohn's disease.
Established in 2014, Roivant Sciences Ltd. is headquartered in London, United Kingdom. For further information, visit their website at https://roivant.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
ROIV Stock Overview
| Market Cap in USD | 9,025m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC SubIndustry | Biotechnology |
| TER | 0.00% |
| IPO / Inception | 2021-10-01 |
ROIV Stock Ratings
| Growth 5y | 0.86 |
| Fundamental | -45.3 |
| Dividend | - |
| Rel. Performance vs Sector | 1.95 |
| Analysts | 4.50/5 |
| Fair Price Momentum | 10.00 USD |
| Fair Price DCF | - |
ROIV Dividends
| Yield 12m | 0.00% |
| Yield on Cost 5y | 0.00% |
| Dividends CAGR 5y | 0.00% |
| Payout Consistency | 0.0% |
ROIV Growth Ratios
| Growth 12m | 29.01% |
| Growth Correlation 12m | 20% |
| Growth Correlation 3m | 6% |
| CAGR 5y | 1.75% |
| Sharpe Ratio 12m | 0.46 |
| Alpha vs SP500 12m | 4.57 |
| Beta vs SP500 5y weekly | 1.03 |
| ValueRay RSI | 49.66 |
| Volatility GJR Garch 1y | 31.07% |
| Price / SMA 50 | 0.82% |
| Price / SMA 200 | 3.67% |
| Current Volume | 3109.7k |
| Average Volume 20d | 6767.7k |
External Links for ROIV Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of April 27, 2024, the stock is trading at USD 11.03 with a total of 3,109,700 shares traded.
Over the past week, the price has changed by +5.45%, over one month by +9.42%, over three months by +6.36% and over the past year by +27.66%.
According to ValueRays Forecast Model, ROIV Roivant Sciences will be worth about 11.2 in April 2025. The stock is currently trading at 11.03. This means that the stock has a potential upside of +1.18%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 16.6 | 50.0 |
| Analysts Target Price | 16.2 | 47.1 |
| ValueRay Target Price | 11.2 | 1.18 |